Outlook ONS-5010 BLA Accepted; FDA Target Date Dec 31, 2025

Outlook Therapeutics' potential new treatment, ONS-5010 (LYTENAVA), is under FDA review following a successful BLA resubmission. The decision is expected by December 31, 2025.